Why Moderna Shares Climbed 228.3% in the First Half
Moderna (NASDAQ: MRNA) shares soared 228.3% in the first half, according to data provided by S&P Global Market Intelligence, as the company advanced its COVID-19 vaccine through clinical studies and announced promising early data.
Image source: Getty Images.
Moderna became the first company to begin clinical trials on a vaccine as the coronavirus spread throughout the world. The company's vaccine candidate entered a phase 1 study in March, then began phase 2 in May.
Source Fool.com
